DUBLIN, Ohio, Aug. 5 /PRNewswire-FirstCall/ -- Cardinal Health, Inc., the leading provider of products and services to the health care industry, announced today that fourth-quarter revenue grew 15 percent to a record $19.5 billion, driven by demand from hospitals, pharmacies and drug manufacturers, while operational improvements continued to strengthen earnings and deliver strong cash flow.
During the quarter ended June 30, operating earnings declined 9 percent to $532 million from $587 million last year, but continued to strengthen over the first half of fiscal 2005 due to fourth-quarter progress in Cardinal Health’s pharmaceutical distribution and Pyxis products businesses. Diluted earnings per share from continuing operations declined 27 percent to $0.66 from $0.91 last year. Operating cash flow remained strong, reaching $806 million during the quarter, which reflects $250 million used to reduce borrowings under an accounts receivable securitization program.
“Cardinal Health concluded the year with a solid fourth quarter marked by improved execution in most areas, but most notably in pharmaceutical distribution and Pyxis products,” said Robert D. Walter, chairman and chief executive officer. “We continued to generate significant cash flow during the quarter and substantially improved our earnings performance over the first half of the fiscal year. Progress made during the year strengthens our momentum for fiscal 2006.”
Cardinal Health said the results announced today are consistent with guidance it provided on June 27.
Excluding special items of $61 million during the quarter, operating earnings declined 5 percent to $593 million compared to $626 million last year, and diluted earnings per share from continuing operations declined 20 percent to $0.78 from $0.97 in the prior year. After tax, special items for the quarter totaled $52 million or $0.12 per share. Special items for the quarter include restructuring and merger costs, proceeds from a litigation settlement and legal costs. In addition, after-tax, non-recurring charges for the quarter were $44 million or $0.11 per share versus a gain of $0.01 per share in the prior year. Non-recurring charges for the quarter include asset impairments, costs to resolve an outstanding insurance claim related to natural rubber latex litigation, an inventory write-off for non-pharmaceutical products and a tax provision for a planned Homeland Investment Act repatriation.
For the full year, revenue increased 15 percent to $74.9 billion, while operating earnings declined 24 percent to $1.8 billion and diluted earnings per share from continuing operations declined 29 percent to $2.47 compared to $3.47 last year. Excluding special items of $239 million, operating earnings declined 15 percent to $2 billion compared to $2.4 billion last year, and diluted earnings per share from continuing operations declined 19 percent to $2.86 compared to $3.55 last year. In addition, after-tax, non-recurring charges for the year were $132 million or $0.31 per share versus a gain of $0.02 per share in the prior year.
The following table summarizes earnings from continuing operations, diluted earnings per share from continuing operations, after-tax special items and after-tax non-recurring charges for Cardinal Health’s fourth quarter and fiscal 2005. (See the attached financial tables for a reconciliation of the non-GAAP measures used in this release to their comparable GAAP measures and a schedule of non-recurring charges.)
Q4 FY05 Earnings from Diluted EPS Earnings from Diluted EPS Continuing from Continuing Continuing from Continuing Operations Operations Operations Operations ($MM) ($MM) GAAP Consolidated $287 $0.66 $1,076 $2.47 Special Items, after tax $52 $0.12 $171 $0.39 Non-Recurring charges, after tax $44 $0.11 $132 $0.31
In addition, consolidated results during the fourth quarter were affected by a number of notable items (described below in Segment Results), including:
-- $48 million LIFO accounting credit in the Pharmaceutical Distribution and Provider Services segment -- $15 million charge associated with a generic pharmaceutical manufacturer’s bankruptcy in the Pharmaceutical Distribution and Provider Services segment -- $8 million write-down of sterile pharmaceutical inventory in the Pharmaceutical Technologies and Services segment -- $30 million for several one-time items in the Clinical Technologies and Services segment, including the write-off of certain Pyxis inventory related to a comprehensive product-line rationalization completed during the quarter. Fiscal 2005 Highlights
During fiscal 2005, Cardinal Health expanded its market-leading product and service offerings, improved operations to increase the value it delivers customers and made investments in the business for long-term growth.
Significant results for the fiscal year included: -- Strong customer demand, with revenue rising 15 percent to $74.9 billion from $65.1 billion in fiscal 2004. -- Excellent cash flow from operations, which reached $2.9 billion, including net proceeds of $550 million from an accounts receivable securitization program. -- Positive earnings momentum during the second half of the fiscal year. Second-half operating earnings increased more than 60 percent over the first half of fiscal 2005. -- Solid operational progress through restructuring programs and disciplined expense control. Restructuring and efficiency programs initiated during fiscal 2005 enabled Cardinal Health to exceed its goal of improving the company’s cost structure by $125 million. Cardinal Health’s board of directors also approved the second phase of a restructuring program announced in December 2004 estimated to cost $80 million to $100 million. The goal of phase two is to further enhance service to customers through better integration across the company’s business segments, and to continue streamlining and improving internal operations. Annual savings from phase one and phase two are expected exceed $500 million during fiscal 2008. -- Rising returns in the second half of the year, with full-year return on equity reaching 14.8 percent excluding special items. Return on equity for the second half of the fiscal year increased nearly 500 basis points over the first half. -- Significant repurchase of shares, as part of a previously announced program. A total of 4.6 million common shares were bought during the fourth quarter, bringing the number of shares repurchased during the fiscal year to 8.8 million at an average price of $56.76, and completing the $500 million buy-back announced in December 2004. The company has announced plans to purchase an additional $1 billion of shares during fiscal 2006. Segment Results
(Special items are not allocated by reporting segment; however segment results were affected by the non-recurring charges and notable one-time items referenced above and described in more detail in the following discussion. Tables with specific segment results for the fourth quarter and fiscal 2005 year-to-date are attached and available at the Investors page on http://www.cardinalhealth.com .)
Pharmaceutical Distribution and Provider Services
Pharmaceutical Distribution and Provider Services revenue rose 16 percent during the quarter to $15.8 billion. An 18-percent increase in operating earnings to $326 million was due in part to a LIFO accounting credit that lowered the cost of goods sold by $48 million, which was partially offset by inventory write-downs that included a $15 million reserve associated with a generic pharmaceutical manufacturer’s bankruptcy.
Excluding these items, solid earnings growth was the result of an increase in volume to retail chains and a profitable mix of generic drugs. Return on sales during the second half of the year increased more than 80 basis points over the first half in the segment. Cardinal Health also expanded its industry-leading efficiency levels during the quarter by lowering selling, general and administrative expenses as a percent of sales by 15 basis points within pharmaceutical distribution.
Annual revenues for the segment increased 16 percent to $60.8 billion, while operating earnings declined 1 percent to $1 billion for the year. New distribution service agreements reached during the quarter brought the annual number of new contracts with branded pharmaceutical manufacturers to more than 100. These agreements establish non-contingent fees for the distribution services Cardinal Health provides, helping to reduce earnings volatility in the segment.
Medical Products and Services
Medical Products and Services revenue increased 5 percent during the quarter to $2.5 billion, while operating earnings declined 3 percent to $178 million and were negatively affected by a $12-million non-recurring charge to resolve an outstanding insurance claim related to natural rubber latex litigation. Litigation of this matter is now complete and no additional, related charges are anticipated. In addition, certain corporate costs were reallocated to the segment for financial processing services in both the current and prior year. The amounts reallocated were $4.5 million in the fourth quarter and $4.9 million in the fourth quarter of fiscal 2004.
Sales of Cardinal Health’s V.Mueller surgical instruments and Neu-Thera(TM) surgeon gloves were strong during the quarter, offset by weakness in Convertors(R) products. Distribution margins were stable, primarily due to a more favorable mix of private label products. Sales and earnings growth in Europe and Canada continued as important contributors for the segment.
For the year, segment revenue increased 7 percent to $9.8 billion and operating earnings declined 3 percent to $672 million. Operating earnings were lower during the year due to non-recurring charges of $28 million, which includes the fourth-quarter and full-year charges to resolve an outstanding insurance claim related to latex litigation. In addition, the reallocation of corporate costs for financial processing services totaled approximately $18 million in both the current and prior years. Competitive pricing and a significant increase in the cost of raw materials and fuel also contributed to operating-earnings pressure during the year, but was partially offset by disciplined expense-control measures and new sourcing programs. Excluding the non-recurring charge, selling, general and administrative expenses as a percent of sales continued to decline from prior-year levels.
Pharmaceutical Technologies and Services
Pharmaceutical Technologies and Services revenue continued to grow during the quarter, up 6 percent to $782 million, driven by oral technologies, nuclear pharmacy services and packaging services. However, ongoing operational issues within sterile manufacturing caused operating earnings to decline 36 percent to $85 million. Earnings during the quarter were affected by an $8 million write-down of sterile inventory and nearly $7 million in costs to operate a sterile manufacturing facility in Humacao, Puerto Rico, that the company previously announced will close later this year.
Excluding sterile manufacturing, the segment performed well during the quarter with oral technologies, nuclear pharmacy services, and packaging services growing their combined earnings 8 percent over the prior year. In particular, strong sales and earnings contributions came from the development and manufacturing of oral dosage products, including Wyeth’s Advil(R), Abbott’s Kaletra(R), and Adams Respiratory Therapeutics’ Mucinex(R).
For the year, revenue increased 6 percent to nearly $3 billion and operating earnings declined 28 percent to $337 million primarily related to previously identified issues within sterile manufacturing operations. During the year, investments were made to improve existing manufacturing sites, and new facilities in Raleigh, N.C. and Brussels, Belgium remain on schedule for production in fiscal 2007.
Clinical Technologies and Services
(Results for this segment, which include Cardinal Health’s Alaris(R) products, Pyxis(R) products and Clinical Services and Consulting organizations, are being reported for the first time this fiscal year. Prior-year results used in comparisons have been adjusted to include Pyxis and Clinical Services and Consulting, but not Alaris, which was acquired by Cardinal Health in July 2004.)
Hospital and health-system customers continued to select Alaris and Pyxis products over competitors, with strong sales in both product lines contributing to revenue for the quarter of $596 million. Alaris continued to perform well during the quarter and Pyxis operations and installation efficiency improved significantly. As a result, operating earnings improved to $86 million. Earnings were lowered by several one-time items totaling $30 million that include the write-off of certain Pyxis inventory related to a comprehensive product-line rationalization completed during the quarter. A record number of committed contracts for both Alaris and Pyxis led to a record backlog in the segment, establishing strong momentum for fiscal 2006. The Pyxis backlog ended the quarter at $260 million, with 70 percent of orders for its new flagship product, Pyxis MedStation 3000.
For the full year, segment revenue reached $2.2 billion and operating earnings were $273 million. An increasing customer preference for Alaris products moved its intravenous pumps into the market-leading position during 2005, according to an industry report. Operational improvements resulting from the Alaris acquisition met company expectations during its first year as part of Cardinal Health and synergies remain on track to reach $80 million to $100 million of pretax earnings by the end of fiscal 2007.
Outlook
Cardinal Health reiterated its fiscal 2006 earnings-per-share outlook of $3.30 to $3.55 excluding special items, non-recurring charges and the impact of incremental equity compensation expenses. Over the long term, Cardinal Health expects earnings per share excluding special items, non-recurring charges and incremental equity compensation expenses to grow 12 percent to 15 percent annually with an annual goal of returning 50 percent of operating cash flow to shareholders through share buy-backs and dividends. During the next several years, the company’s goal is to increase dividends to up to 20 percent of earnings per share.
Conference Call
Cardinal Health will host a conference call and webcast at 11 a.m. Eastern Daylight Time (EDT) to discuss the fourth quarter and fiscal year results. To access the discussion, go to the Investors page at http://www.cardinalhealth.com or dial 706-634-5100, passcode 7436813. An audio replay will be available until 11 p.m. on Aug. 12 at 706-645-9291, passcode 7436813. A transcript and audio replay will also be available at http://www.cardinalhealth.com .
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. is the leading provider of products and services supporting the health-care industry. Cardinal Health develops, manufactures, packages and markets products for patient care; develops drug-delivery technologies; distributes pharmaceuticals and medical, surgical and laboratory supplies; and offers consulting and other services that improve quality and efficiency in health care. Ranked No. 16 on the Fortune 500, Cardinal Health employs more than 55,000 people on six continents and produces annual revenues of nearly $75 billion. More information about the company may be found at http://www.cardinalhealth.com .
Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health’s Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: the costs, difficulties, and uncertainties related to the integration of acquired businesses; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by any regulatory authority or any legal and administrative proceedings; the impact of previously announced restatements; difficulties or delays or increased costs in implementing its global restructuring program; difficulties in opening new facilities or fully utilizing existing capacity; difficulties and uncertainties associated with business model transitions, including the conversion of margin generated from branded pharmaceutical manufacturers to non-contingent consideration; general economic and market conditions; with respect to future dividends, the decision by the board of directors to declare such dividends, which is expected to consider Cardinal Health’s surplus, earnings, cash flows, financial condition and prospects at the time any such action is considered; and, with respect to future share repurchases, the approval of the board of directors, which is expected to consider Cardinal Health’s then-current stock price, earnings, cash flows, financial condition and prospects as well as alternatives available to Cardinal Health at the time any such action is considered. Cardinal Health undertakes no obligation to update or revise any forward-looking statement.
CARDINAL HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) (in millions, except per Common Share amounts) FOURTH QUARTER June June 2005 2004 % Change Revenue $19,457.1 $16,922.7 15 % Cost of products sold 18,083.7 15,698.7 15 % Gross margin 1,373.4 1,224.0 12 % Selling, general and administrative expenses 765.7 602.1 27 % Impairment charges and other 15.0 (4.5) N.M. Special items Restructuring charges 64.6 12.0 N.M. Merger charges 11.4 21.1 N.M. Foundation contribution - 31.7 N.M. Other (15.1) (25.4) N.M. Operating earnings 531.8 587.0 (9)% Interest expense and other 38.4 28.3 36 % Earnings before income taxes and discontinued operations 493.4 558.7 (12)% Provision for income taxes 206.4 161.3 28 % Earnings from continuing operations 287.0 397.4 (28)% Earnings/(loss) from discontinued operations (net of tax ($0.1) and $2.6 for the quarters ending June 30, 2005 and 2004, respectively) 0.2 (3.9) N.M. Net earnings $287.2 $393.5 N.M. Basic earnings per Common Share: Continuing operations $0.67 $0.92 (27)% Discontinued operations - (0.01) N.M. Net basic earnings per Common Share $0.67 $0.91 N.M. Diluted earnings per Common Share: Continuing operations $0.66 $0.91 (27)% Discontinued operations - (0.01) N.M. Net diluted earnings per Common Share $0.66 $0.90 N.M. Weighted average number of shares outstanding: Basic 426.8 430.4 Diluted 432.4 436.7 The following table summarizes the impact of special items on net earnings and diluted earnings per Common Share in the quarters in which they were recorded: Current Year Prior Year Net Diluted Net Diluted Earnings EPS Earnings EPS Impact of special items Restructuring charges $(54.7) $(0.12) $(7.9) $(0.02) Merger charges (6.9) (0.02) (13.2) (0.03) Foundation contribution - - (21.3) (0.05) Other 9.9 0.02 17.1 0.04 Impact of special items $(51.7) $(0.12) $(25.3) $(0.06) CARDINAL HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) (in millions, except per Common Share amounts) YEAR - TO - DATE June June 2005 2004 % Change Revenue $74,910.7 $65,053.5 15 % Cost of products sold 69,897.5 60,312.3 16 % Gross margin 5,013.2 4,741.2 6 % Selling, general and administrative expenses 2,861.5 2,346.5 22 % Impairment charges and other 118.0 (11.5) N.M. Special items Restructuring charges 203.0 37.1 N.M. Merger charges 48.9 44.7 N.M. Foundation contribution - 31.7 N.M. Other (12.7) (56.1) N.M. Operating earnings 1,794.5 2,348.8 (24)% Interest expense and other 133.5 110.4 21 % Earnings before income taxes, discontinued operations and cumulative effect of change in accounting 1,661.0 2,238.4 (26)% Provision for income taxes 584.8 713.7 (18)% Earnings from continuing operations before cumulative effect of change in accounting 1,076.2 1,524.7 (29)% Earnings/(loss) from discontinued operations (net of tax ($2.6) and $7.4 for the year-to-date periods ended June 30, 2005 and 2004, respectively) 4.0 (11.7) N.M. Cumulative effect of change in accounting - (38.5) N.M. Net earnings $1,080.2 $1,474.5 N.M. Basic earnings per Common Share: Continuing operations $2.50 $3.51 (29)% Discontinued operations 0.01 (0.03) N.M. Cumulative effect of change in accounting - (0.09) N.M. Net basic earnings per Common Share $2.51 $3.39 N.M. Diluted earnings per Common Share: Continuing operations $2.47 $3.47 (29)% Discontinued operations 0.01 (0.03) N.M. Cumulative effect of change in accounting - (0.09) N.M. Net diluted earnings per Common Share $2.48 $3.35 N.M. Weighted average number of shares outstanding: Basic 430.5 434.4 Diluted 435.7 440.0 The following table summarizes the impact of special items on net earnings and diluted earnings per Common Share in the years in which they were recorded: Current Year Prior Year Net Diluted Net Diluted Earnings EPS Earnings EPS Impact of special items Restructuring charges $(148.9) $(0.34) $(24.4) $(0.06) Merger charges (30.8) (0.07) (27.7) (0.06) Foundation contribution - - (21.3) (0.05) Other 8.4 0.02 37.8 0.09 Impact of special items $(171.3) $(0.39) $(35.6) $(0.08) CARDINAL HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in millions) June 30, March 31, June 30, 2005 2005 2004 ASSETS Cash and equivalents $1,411.7 $1,549.5 $1,096.0 Short-term investments 99.8 - - Trade receivables, net 3,451.0 3,293.0 3,432.7 Current portion of net investment in sales-type leases 238.2 215.3 202.1 Inventories 7,391.6 7,771.3 7,471.3 Prepaid expenses and other 851.1 871.9 795.4 Assets held for sale from discontinued operations - 28.2 60.4 Total current assets 13,443.4 13,729.2 13,057.9 Property and equipment, net 2,484.0 2,372.0 2,364.0 Net investment in sales-type leases, less current portion 693.8 640.9 546.0 Other assets 5,438.8 5,396.4 5,401.2 TOTAL ASSETS $22,060.0 $22,138.5 $21,369.1 LIABILITIES AND SHAREHOLDERS’ EQUITY Notes payable - banks and current portion of long-term obligations $279.7 $588.6 $860.6 Accounts payable 7,627.5 7,613.1 6,432.4 Other accrued liabilities 2,153.8 1,802.7 2,021.3 Liabilities from discontinued operations - 44.6 55.1 Total current liabilities 10,061.0 10,049.0 9,369.4 Long-term obligations, less current portion 2,335.2 2,303.1 2,834.7 Deferred taxes and other liabilities 1,041.3 1,112.2 1,188.7 Total shareholders’ equity 8,622.5 8,674.2 7,976.3 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $22,060.0 $22,138.5 $21,369.1 CARDINAL HEALTH, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in millions) Three Months Ended For the Year Ended June 30, June 30, 2005 2004 2005 2004 Cash Flows From Operating Activities: Earnings from continuing operations before cumulative effect of change in accounting $287.0 $397.4 $1,076.2 $1,524.7 Adjustments to reconcile earnings from continuing operations before cumulative effect of change in accounting to net cash from operations: Depreciation and amortization 108.8 78.8 409.7 299.2 Asset impairments 51.0 0.2 223.9 5.7 Change in operating assets and liabilities, net of effects from acquisitions: Decrease/(increase) in trade receivables (158.0) 156.7 (6.1) (455.6) Decrease in inventories 379.7 1,153.1 78.5 209.3 Decrease/(increase) in net investment in sales-type leases (75.8) 58.2 (183.9) (7.2) Increase/(decrease) in accounts payable 14.4 (597.3) 1,189.6 1,014.6 Other accrued liabilities and operating items, net 199.2 42.2 69.3 34.0 Net cash provided by operating activities 806.3 1,289.3 2,857.2 2,624.7 Cash Flows From Investing Activities: Acquisition of subsidiaries, net of cash acquired - (1,528.5) (273.2) (2,089.7) Proceeds from sale of property, equipment, and other assets 1.2 11.2 19.9 19.5 Additions to property and equipment (280.0) (138.2) (568.3) (410.2) Proceeds from sale of discontinued operations 7.9 38.3 47.4 43.4 Purchase of investment securities available for sale (99.8) - (99.8) - Net cash used in investing activities (370.7) (1,617.2) (874.0) (2,437.0) Cash Flows From Financing Activities: Net change in commercial paper and short-term debt (3.3) 647.1 (561.4) 646.2 Net change in long-term obligations (308.8) 229.8 (664.6) (126.3) Proceeds from issuance of Common Shares 23.3 72.4 110.5 216.7 Purchase of Treasury Shares (271.8) (39.7) (500.3) (1,500.0) Dividends on Common Shares (12.8) (12.9) (51.7) (52.3) Net cash provided by/(used in) financing activities (573.4) 896.7 (1,667.5) (815.7) Net Increase/(Decrease) in Cash and Equivalents (137.8) 568.8 315.7 (628.0) Cash and Equivalents at Beginning of Period 1,549.5 527.2 1,096.0 1,724.0 Cash and Equivalents at End of Period $1,411.7 $1,096.0 $1,411.7 $1,096.0 CARDINAL HEALTH, INC. AND SUBSIDIARIES FOURTH QUARTER FY 2005 BUSINESS ANALYSIS ($ millions) PHARMACEUTICAL DISTRIBUTION AND PROVIDER SERVICES MEDICAL PRODUCTS AND SERVICES (1) 2005 2004 2005 2004 REVENUE REVENUE - Amount $15,776 $13,566 - Amount $2,532 $2,405 - Growth Rate 16 % 12 % - Growth Rate 5 % 14 % - Mix 80 % 79 % - Mix 13 % 14 % OPERATING EARNINGS OPERATING EARNINGS - Amount $326 $277 - Amount $178 $184 - Growth Rate 18 % (3)% - Growth Rate (3)% 14 % - Mix 48 % 41 % - Mix 26 % 27 % - Ratio to - Ratio to Revenue 2.07% 2.04% Revenue 7.05% 7.66% PHARMACEUTICAL TECHNOLOGIES AND SERVICES CLINICAL TECHNOLOGIES AND SERVICES (2) 2005 2004 2005 2004 REVENUE REVENUE - Amount $782 $740 - Amount $596 $424 - Growth Rate 6 % 4 % - Growth Rate 40 % 11 % - Mix 4 % 5 % - Mix 3 % 2 % OPERATING EARNINGS OPERATING EARNINGS - Amount $85 $132 - Amount $86 $87 - Growth Rate (36)% 14 % - Growth Rate (1)% (12)% - Mix 13 % 19 % - Mix 13 % 13 % - Ratio to - Ratio to Revenue 10.86% 17.81% Revenue 14.43% 20.43% (1) Certain expenses of Cardinal Health’s shared services center in Albuquerque, New Mexico have been classified within the Medical Products and Services segment. These expenses were $4.5 million and $4.6 million in fiscal 2005 and 2004, respectively. (2) The fiscal 2004 results for the Clinical Technologies and Services segment have been adjusted to include Pyxis and Clinical Services and Consulting, but not Alaris, which was acquired by Cardinal Health in July 2004. CARDINAL HEALTH, INC. AND SUBSIDIARIES FOURTH QUARTER FY 2005 BUSINESS ANALYSIS ($ millions) EXCLUDING TOTAL SPECIAL ITEMS 2005 2004 2005 2004 REVENUE - Amount $19,457 $16,923 - Growth Rate 15 % 11 % OPERATING EARNINGS - Amount $532 $587 $593 $626 - Growth Rate (9)% 7 % (5)% 5 % RATIO TO REVENUE - Gross Margin 7.06% 7.23% - Expenses 3.94% 3.56% - Impairment Charges and Other 0.08% (0.03)% - Special Items 0.31% 0.23 % - Operating Earnings 2.73% 3.47% 3.04% 3.70% EARNINGS FROM CONTINUING OPERATIONS * - Amount $287 $397 $339 $423 - Growth Rate (28)% 11% (20)% 8% - Ratio to Revenue 1.48% 2.35% 1.74% 2.50% PRODUCTIVITY - Margin per Expense Dollar $1.79 $2.03 ASSET MANAGEMENT - Operating Cash Flow $806 $1,289 - Free Cash Flow $515 $1,149 - Return on Invested Capital 5.86% 8.12% 6.87% 8.61% * The earnings from continuing operations section is presented before the cumulative effect of change in accounting. Margin per Expense Dollar = Ratio of Gross Margin to Expenses See the GAAP/NON-GAAP RECONCILIATION schedule for the calculations and definitions supporting the balances excluding special items. CARDINAL HEALTH, INC. AND SUBSIDIARIES FISCAL YEAR 2005 BUSINESS ANALYSIS ($ millions) PHARMACEUTICAL DISTRIBUTION AND PROVIDER SERVICES MEDICAL PRODUCTS AND SERVICES (1) 2005 2004 2005 2004 REVENUE REVENUE - Amount $60,844 $52,334 - Amount $9,824 $9,143 - Growth Rate 16% 14% - Growth Rate 7% 14% - Mix 80% 80% - Mix 13% 14% OPERATING EARNINGS OPERATING EARNINGS - Amount $1,047 $1,062 - Amount $672 $695 - Growth Rate (1)% (2)% - Growth Rate (3)% 11% - Mix 45% 42% - Mix 29% 27% - Ratio to - Ratio to Revenue 1.72% 2.03% Revenue 6.85% 7.60% PHARMACEUTICAL TECHNOLOGIES AND SERVICES CLINICAL TECHNOLOGIES AND SERVICES (2) 2005 2004 2005 2004 REVENUE REVENUE - Amount $2,976 $2,804 - Amount $2,189 $1,551 - Growth Rate 6% 25% - Growth Rate 41% 10% - Mix 4% 4% - Mix 3% 2% OPERATING EARNINGS OPERATING EARNINGS - Amount $337 $465 - Amount $273 $337 - Growth Rate (28)% 26 % - Growth Rate (19)% 6% - Mix 14% 18% - Mix 12% 13% - Ratio to - Ratio to Revenue 11.33% 16.60% Revenue 12.48% 21.71% (1) Certain expenses of Cardinal Health’s shared services center in Albuquerque, New Mexico have been classified within the Medical Products and Services segment. These expenses were $18.2 million and $18.5 million in fiscal 2005 and 2004, respectively. (2) The fiscal 2004 results for the Clinical Technologies and Services segment have been adjusted to include Pyxis and Clinical Services and Consulting, but not Alaris, which was acquired by Cardinal Health in July 2004. CARDINAL HEALTH, INC. AND SUBSIDIARIES FISCAL YEAR 2005 BUSINESS ANALYSIS ($ millions) EXCLUDING TOTAL SPECIAL ITEMS 2005 2004 2005 2004 REVENUE - Amount $74,911 $65,053 - Growth Rate 15% 15% OPERATING EARNINGS - Amount $1,795 $2,349 $2,034 $2,406 - Growth Rate (24)% 7% (15)% 8% RATIO TO REVENUE - Gross Margin 6.70% 7.29% - Expenses 3.82% 3.61% - Impairment Charges and Other 0.16% (0.02)% - Special Items 0.32% 0.09% - Operating Earnings 2.40% 3.61% 2.72% 3.70% EARNINGS FROM CONTINUING OPERATIONS * - Amount $1,076 $1,525 $1,248 $1,560 - Growth Rate (29)% 10% (20)% 10% - Ratio to Revenue 1.44% 2.34% 1.67% 2.40% PRODUCTIVITY - Margin per Expense Dollar $1.75 $2.02 ASSET MANAGEMENT - Operating Cash Flow $2,857 $2,625 - Free Cash Flow $2,257 $2,182 - Return on Invested Capital 5.49% 7.96% 6.31% 8.14% * The earnings from continuing operations section is presented before the cumulative effect of change in accounting. Margin per Expense Dollar = Ratio of Gross Margin to Expenses See the GAAP/NON-GAAP RECONCILIATION schedule for the calculations and definitions supporting the balances excluding special items. CARDINAL HEALTH, INC. AND SUBSIDIARIES QUARTERLY FY 2005 BUSINESS ANALYSIS PHARMACEUTICAL DISTRIBUTION AND PROVIDER SERVICES ($ millions) Q1 Q2 Q3 Q4 TOTAL REVENUE - Amount $14,402 $15,059 $15,608 $15,776 $60,844 - Growth Rate 16% 15% 18% 16% 16% - Mix 80% 80% 80% 80% 80% OPERATING EARNINGS - Amount $163 $213 $344 $326 $1,047 - Growth Rate (29)% (9)% 8 % 18 % (1)% - Mix 38% 39% 50% 48% 45% - Ratio to Revenue 1.13% 1.42% 2.20% 2.07% 1.72% MEDICAL PRODUCTS AND SERVICES (1) Q1 Q2 Q3 Q4 TOTAL REVENUE - Amount $2,393 $2,427 $2,473 $2,532 $9,824 - Growth Rate 11% 6% 7% 5% 7% - Mix 13% 13% 13% 13% 13% OPERATING EARNINGS - Amount $134 $165 $195 $178 $672 - Growth Rate (14)% - 3% (3)% (3)% - Mix 32% 31% 28% 26% 29% - Ratio to Revenue 5.57% 6.81% 7.89% 7.05% 6.85% PHARMACEUTICAL TECHNOLOGIES AND SERVICES Q1 Q2 Q3 Q4 TOTAL REVENUE - Amount $705 $760 $729 $782 $2,976 - Growth Rate 9% 7% 3% 6% 6% - Mix 4% 4% 4% 4% 4% OPERATING EARNINGS - Amount $81 $89 $82 $85 $337 - Growth Rate (24)% (22)% (28)% (36)% (28)% - Mix 19% 16% 12% 13% 14 % - Ratio to Revenue 11.46% 11.68% 11.31% 10.86% 11.33% CLINICAL TECHNOLOGIES AND SERVICES (2) Q1 Q2 Q3 Q4 TOTAL REVENUE - Amount $524 $547 $522 $596 $2,189 - Growth Rate 57% 38% 32% 40% 41% - Mix 3% 3% 3% 3% 3% OPERATING EARNINGS - Amount $46 $76 $65 $86 $273 - Growth Rate (32)% (21)% (25)% (1)% (19)% - Mix 11 % 14 % 10 % 13 % 12 % - Ratio to Revenue 8.76% 13.89% 12.50% 14.43% 12.48% (1) Certain expenses of the Cardinal Health’s shared services center in Albuquerque, New Mexico have been classified within the Medical Products and Services segment. These expenses were $4.7 million, $4.6 million, $4.4 million and $4.5 million in fiscal 2005, respectively, and were $4.6 million, $4.7 million, $4.6 million and $4.6 million in fiscal 2004, respectively. (2) The fiscal 2004 results for the Clinical Technologies and Services segment have been adjusted to include Pyxis and Clinical Services and Consulting, but not Alaris, which was acquired by Cardinal Health in July 2004. The sum of the quarters may not equal year-to-date due to rounding CARDINAL HEALTH, INC. AND SUBSIDIARIES QUARTERLY FY 2005 BUSINESS ANALYSIS (EXCLUDING SPECIAL ITEMS) ($ millions) Q1 Q2 Q3 Q4 TOTAL REVENUE - Amount $17,796 $18,555 $19,103 $19,457 $74,911 - Growth Rate 16% 13% 17% 15% 15% OPERATING EARNINGS - Amount $390 $424 $628 $593 $2,034 - Growth Rate (26)% (27)% (7)% (5)% (15)% RATIO TO REVENUE - Gross Margin 6.10% 6.50% 7.05% 7.06% 6.70% - Expenses 3.89% 3.77% 3.68% 3.94% 3.82% - Impairment Charges and Other 0.02% 0.45% 0.08% 0.08% 0.16% - Operating Earnings 2.19% 2.28% 3.29% 3.04% 2.72% EARNINGS FROM CONTINUING OPERATIONS * - Amount $238 $275 $396 $339 $1,248 - Growth Rate (28)% (26)% (9)% (20)% (20)% - Ratio to Revenue 1.34% 1.48% 2.07% 1.74% 1.67% PRODUCTIVITY - Margin Per Expense Dollar $1.57 $1.72 $1.92 $1.79 $1.75 ASSET MANAGEMENT - Operating Cash Flow $893 $626 $532 $806 $2,857 - Free Cash Flow $777 $506 $460 $515 $2,257 - Return on Invested Capital 4.95% 5.42% 8.01% 6.87% 6.31% * The earnings from continuing operations section is presented before the cumulative effect of change in accounting. Margin Per Expense Dollar = Ratio of Gross Margin to Expenses The sum of the quarters may not equal year-to-date due to rounding See the GAAP/NON-GAAP RECONCILIATION schedule for the calculations and definitions supporting the balances excluding special items. CARDINAL HEALTH, INC. AND SUBSIDIARIES FISCAL 2005 AND 2004 ASSET MANAGEMENT ANALYSIS ($ millions) 2005 Q1 Q2 Q3 Q4 YTD RECEIVABLE DAYS 16.4 13.3 14.8 16.0 DAYS INVENTORY ON HAND 39 38 35 33 CASH AND EQUIVALENTS $1,152 $1,274 $1,550 $1,412 DEBT $3,255 $2,820 $2,892 $2,615 EQUITY $8,219 $8,559 $8,674 $8,623 NET DEBT/TOTAL CAPITAL * 20 % 15 % 13 % 11 % TANGIBLE NET WORTH * * $3,200 $3,519 $3,676 $3,525 RETURN ON EQUITY 10.8% 9.7% 17.1% 13.3% 12.8% RETURN ON EQUITY - EXCLUDING SPECIAL ITEMS 11.7% 13.0% 18.3% 15.6% 14.8% TAX RATE FROM CONTINUING OPERATIONS 32.0% 32.9% 32.3% 41.8% 35.2% TAX RATE FROM CONTINUING OPERATIONS - EXCLUDING SPECIAL ITEMS 32.5% 32.5% 32.5% 38.9% 34.3% 2004 Q1 Q2 Q3 Q4 YTD RECEIVABLE DAYS 17.5 17.4 17.5 17.7 DAYS INVENTORY ON HAND 45 44 45 38 CASH AND EQUIVALENTS $992 $544 $527 $1,096 DEBT $2,724 $2,726 $2,532 $3,695 EQUITY $6,993 $7,456 $7,522 $7,976 NET DEBT/TOTAL CAPITAL * 20 % 23 % 21 % 25 % TANGIBLE NET WORTH * * $4,653 $4,558 $4,520 $3,038 RETURN ON EQUITY 17.6% 20.7% 23.0% 20.5% 20.3% RETURN ON EQUITY - EXCLUDING SPECIAL ITEMS 18.1% 20.5% 23.2% 21.8% 20.7% TAX RATE FROM CONTINUING OPERATIONS 33.2% 32.9% 32.7% 28.9% 31.9% TAX RATE FROM CONTINUING OPERATIONS - EXCLUDING SPECIAL ITEMS 33.2% 33.1% 32.8% 29.3% 32.0% * Net debt to total capital = net debt/(net debt + shareholders’ equity) Net debt = long-term obligations + short-term obligations + notes payable banks - cash and equivalents - short-term investments * * Tangible net worth = shareholders’ equity - goodwill and other intangibles CARDINAL HEALTH, INC. AND SUBSIDIARIES GAAP/NON-GAAP RECONCILIATION ($ millions) FOURTH QUARTER FISCAL 2005 GAAP* Special Excluding Basis Items Special Items REVENUE - Amount $19,457 - $19,457 SPECIAL ITEMS - Restructuring Charges $65 $65 - - Merger Charges 11 11 - - Foundation Contribution - - - - Other ($15) ($15) - OPERATING EARNINGS - Amount $532 $61 $593 - Growth Rate (9)% (5)% - Ratio to Revenue (Return on Sales) 2.73% 3.04% EARNINGS BEFORE INCOME TAXES - Amount $493 $61 $554 INCOME TAX PROVISION - Amount $206 $9 $215 EARNINGS FROM CONTINUING OPERATIONS - Amount $287 $52 $339 - Growth Rate (28)% (20)% - Ratio to Revenue 1.48% 1.74% - Diluted EPS $0.66 $0.12 $0.78 CARDINAL HEALTH, INC. AND SUBSIDIARIES GAAP/NON-GAAP RECONCILIATION ($ millions) FISCAL 2005 GAAP* Special Excluding Basis Items Special Items REVENUE - Amount $74,911 - $74,911 SPECIAL ITEMS - Restructuring Charges $203 $203 - - Merger Charges 49 49 - - Foundation Contribution - - - - Other ($13) ($13) - OPERATING EARNINGS - Amount $1,795 $239 $2,034 - Growth Rate (24)% (15)% - Ratio to Revenue (Return on Sales) 2.40% 2.72% EARNINGS BEFORE INCOME TAXES - Amount $1,661 $239 $1,900 INCOME TAX PROVISION - Amount $585 $67 $652 EARNINGS FROM CONTINUING OPERATIONS - Amount $1,076 $172 $1,248 - Growth Rate (29)% (20)% - Ratio to Revenue 1.44% 1.67% - Diluted EPS $2.47 $0.39 $2.86 FOURTH QUARTER FISCAL 2004 GAAP* Special Excluding Basis Items Special Items REVENUE - Amount $16,923 - $16,923 SPECIAL ITEMS - Restructuring Charges $12 $12 - - Merger Charges 21 21 - - Foundation Contribution 31 31 - - Other ($25) ($25) - OPERATING EARNINGS - Amount $587 $39 $626 - Growth Rate 7% 5% - Ratio to Revenue (Return on Sales) 3.47% 3.70% EARNINGS BEFORE INCOME TAXES - Amount $559 $39 $598 INCOME TAX PROVISION - Amount $161 $13 $174 EARNINGS FROM CONTINUING OPERATIONS - Amount $397 $26 $423 - Growth Rate 11% 8% - Ratio to Revenue 2.35% 2.50% - Diluted EPS $0.91 $0.06 $0.97 FISCAL 2004 GAAP* Special Excluding Basis Items Special Items REVENUE - Amount $65,054 - $65,054 SPECIAL ITEMS - Restructuring Charges $37 $37 - - Merger Charges 45 45 - - Foundation Contribution 31 31 - - Other ($56) ($56) - OPERATING EARNINGS - Amount $2,349 $57 $2,406 - Growth Rate 7% 8% - Ratio to Revenue (Return on Sales) 3.61% 3.70% EARNINGS BEFORE INCOME TAXES - Amount $2,238 $57 $2,295 INCOME TAX PROVISION - Amount $714 $22 $736 EARNINGS FROM CONTINUING OPERATIONS - Amount $1,525 $35 $1,560 - Growth Rate 10% 10% - Ratio to Revenue 2.34% 2.40% - Diluted EPS $3.47 $0.08 $3.55 FREE CASH FLOW ($ millions) Fiscal Fiscal Q4 FY05 Q4 FY04 2005 2004 Net cash provided by operating activities $806 $1,289 $2,857 $2,625 ADD: - Proceeds from sale of property and equipment 2 11 20 19 LESS: - Additions to property and equipment (280) (138) (568) (410) - Dividends on common shares (13) (13) (52) (52) Free Cash Flow $515 $1,149 $2,257 $2,182 DEFINITIONS: * GAAP - Amounts that conform with generally accepted accounting principles. Return on equity (excluding special items) = (Earnings from continuing operations + special items after tax) /average shareholders’ equity Note: Average shareholders’ equity used in the return on equity calculation was $8.7 billion and $7.8 billion in the fourth quarter of fiscal 2005 and 2004, respectively, and $8.4 billion and $7.5 billion for year to date of fiscal 2005 and 2004, respectively. Effective tax rate (excluding special items) = (Income tax provision + tax effect of special items) / (earnings before income taxes + special items) Growth rate (excluding special items) = (Current quarter earnings excluding special items - prior year quarter earnings excluding special items)/prior year quarter earnings excluding special items Ratio to revenue (excluding special items) = Current quarter earnings excluding special items/revenue Return on invested capital (excluding special items) = [Operating earnings excluding special items annualized x (1-effective tax rate, excluding special items)]/average (equity +debt + unrecorded goodwill) Note: Average unrecorded goodwill used in return on invested capital calculation was $9.7 billion in fiscal 2005 and fiscal 2004. CARDINAL HEALTH, INC. AND SUBSIDIARIES RECONCILIATION OF NON-RECURRING CHARGES ($ millions) Q4 FY05 YTD FY05 Impairment charges and other $(15.0) $(118.0) Less: minority interest and realized currency translation adjustment - 19.4 Net impairment charges (15.0) (98.6) Alaris inventory adjustment - (23.6) Latex litigation (11.8) (28.2) Inventory adjustment - SKU rationalization (0.6) (7.8) Non-recurring charges before tax impact and HIA repatriation (27.4) (158.2) Tax impact 9.4 52.1 Sub total (18.0) (106.1) HIA repatriation tax provision (26.3) (26.3) Impact on net earnings $(44.3) $(132.4) Weighted average diluted number of shares outstanding 432.4 435.7 Impact on EPS $(0.11) $(0.31) Q4 FY04 YTD FY04 Impairment charges and other $4.5 $11.5 Tax impact (1.3) (3.7) Impact on net earnings $3.2 $7.8 Weighted average diluted number of shares outstanding 436.7 440.0 Impact on EPS $0.01 $0.02
Cardinal Health, Inc.
CONTACT: Media: Jim Mazzola, +1-614-757-3690, jim.mazzola@cardinal.com,Investors: Jim Hinrichs, +1-614-757-7828, jim.hinrichs@cardinal.com, bothof Cardinal Health, Inc.
Web site: http://www.cardinalhealth.com/